EASME

A French startup created by CNRS researchers at the Physics and Mechanics of Heterogeneous Media (PMMH) Laboratory in Paris, Aenitis Technologies develops bioprocessing medical devices that use acoustophoresis to separate, manipulate and filter biological elements, with a focus on cell therapy manufacturing such as cell sorting, washing and isolation for cell therapy units and blood banks. The company aims to provide acoustic preparation solutions to streamline cell therapies and advance public health, pursuing leadership in acoustophoresis-based separation.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Brevel develops innovative cultivation technology for sustainable, low-cost production of microalgae. Its high-tech, indoor, automated systems use internal illumination to achieve over 90% cost reduction and up to 200 times higher yields compared to traditional methods. Brevel targets various markets where microalgae-derived products are in demand.

Trovant Technology SL, established in 2018 and headquartered in Valladolid, Spain, specializes in developing bio-based technologies for organic waste treatment and valorization. The company's primary focus is transforming waste into valuable products such as bioenergy or biomaterials, with a particular emphasis on biogas upgrading and biomethane production using its proprietary UBI technology. It offers tailored solutions to the environmental sector, including products for anaerobic digestion, wastewater treatment, bioindication, and bioinformatics.

InterAx Biotech Ltd is a biotechnology company based in Villigen, Switzerland, focused on developing a platform for the discovery of functionally selective drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 2016, the company integrates bioanalytical methods and computational pharmacology to assist in drug candidate design and selection. Its innovative platform combines high-throughput biochemical screening with artificial intelligence and mathematical modeling of cell signaling, facilitating the identification and optimization of drug candidates for various diseases, including those associated with orphan GPCRs. Through its advanced approach, InterAx Biotech aims to improve drug efficacy while reducing side effects, contributing to the healthcare industry's efforts to discover safer and more effective treatments.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

CH-Bioforce provides a revolutionary technology for converting all biomass components into high-value material streams - dissolving pulp, polymeric hemicellulose, and sulphur-free lignin. These valuable biomaterials can replace fossil and food-based raw materials in multiple industries, such as textiles and packaging applications.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Neuro Device Group S.A. is a Polish med-tech company, established in 2008 and based in Warsaw, specializing in the development and manufacturing of medical devices aimed at addressing neurological disorders. The company's product lineup includes Neuro Device Camri, a diagnostic recording camera for MRI scanners; Neuro Device Scent, which measures neuronal reactions to scents; and Neuro Device Tacti, a stimulator used in preoperative fMRI diagnostics to localize brain sensomotoric areas. In addition to its proprietary devices, Neuro Device Group also distributes a range of high-quality neurological products and medical devices from leading global manufacturers, encompassing areas such as eye tracking, rehabilitation, virtual reality, and fMRI. The company's ongoing mission is to enhance neurological research and improve patient outcomes through innovative technologies.

Planktovie develops and markets nutritional solutions and care platforms for aquatic organisms, supporting scientific research and aquarium hobbyists. The company provides specialized diets, live food cultures, water treatment solutions, and expert guidance to help researchers and hobbyists maintain healthy, thriving aquatic environments, advance scientific discovery, and foster appreciation of aquatic ecosystems.

Elypta develops a liquid biopsy platform using metabolism-based biomarkers and artificial intelligence. Its platform measures glycosaminoglycan metabolites in blood and urine, aiming to enable earlier detection and monitoring of various cancer types.

Probiomedica is a company focused on developing innovative biomedical devices that integrate engineering, biology, photonics, and robotics for health and personal care applications. The company specializes in creating small swallowable capsules designed to emit light at specific wavelengths, utilizing the principles of Photodynamic therapy. This technology aims to enhance the photo-killing of harmful bacteria such as Helicobacter pylori, which is associated with conditions like gastritis, peptic ulcers, and gastric cancer. By employing these advanced photonic techniques, Probiomedica seeks to offer effective treatments that minimize reliance on pharmaceuticals and reduce the risk of drug-related side effects, thereby improving patient outcomes in the realm of gastrointestinal health.

Zymvol accelerates the discovery & development of new industrial enzymes through computer simulations.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

BioMensio develops smart handheld devices for rapid, on-site detection of multiple biological targets. Its core technology enables label-free assays and facilitates development of new bio-screening applications. The company's products include BioMensio devices and a novel miniaturized microarray platform, serving point-of-care, food safety, and bio-security applications.

Cyclomics is a Dutch startup dedicated to transforming cancer care by facilitating faster and more reliable diagnoses, particularly for cancer recurrence. It achieves this through its proprietary circulating tumor DNA (ctDNA) detection technology, CyclomicsSeq. Initially focused on head and neck cancers, the company aims to disrupt cancer diagnostics markets and clinical practices with its innovative solution.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

Surgitate is a Turkish startup founded by Ozge Akbulut (PhD in Materials Engineering) and Barkın Eldem (MD, Thoracic Surgeon). They manufacture synthetic models for medical professionals and students to practice surgical procedures realistically. Their product range includes skin, breast, and vascular models designed to mimic incision, dissection, and suturing. Surgitate benefits from investments by Farplas, a leading automotive parts manufacturer, which aids in mass production processes, and Inovent, Turkey's first tech commercialization accelerator, facilitating connections with potential investors and customers.

InProcess-LSP, founded in 2014 by former MSD/Merck employees, develops process analytical technologies for nanoscale particle analysis. Based in Oss, The Netherlands, at Pivot Park alongside more than 35 life-science companies, the company focuses on a real-time, non-invasive device that measures particle size and size distribution in turbid nanosuspensions without sample treatment or dilution. This technology supports pharmaceutical and biopharmaceutical manufacturing by improving process efficiency, enabling tighter quality control, and shortening development timelines.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of advanced hearing solutions aimed at addressing various levels of hearing impairment. As a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic in Tübingen, Vibrosonic focuses on innovative technologies that enhance the auditory experience for users. The company has created hearing contact lenses that utilize microsystem technology and a piezoelectric principle, enabling sound transmission through vibrations directly to the eardrum. This approach offers a discreet alternative to traditional hearing aids, improving comfort and usability for individuals with hearing loss.

Double Bond Pharmaceutical is a pharmaceutical company that develops and commercializes innovative first-in-class therapies for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders. It aims to provide patients and markets with safer, more effective products in areas where medical needs remain unmet.

Crop Intellect is a research and development company focused on enhancing agricultural productivity through innovative technologies. It offers cultivation consultancy services, develops advanced crop nutrition products, plant technology sensors, and smart farming techniques to increase crop yields, improve fruit uniformity, extend shelf life, and reduce agrochemical inputs.

PolyPico Ltd is a Cork, Ireland-based company specializing in innovative fluid dispensing technology, stemming from five years of research at the University of Limerick. The company designs and manufactures advanced fluid dispensing solutions for both Life Science and Industrial applications. Recognized as a leading microdispensing specialist, PolyPico's technology is utilized by renowned institutions such as NASA and Harvard. Its core platform focuses on non-contact ultra-low volume acoustic dispensing, enabling precise liquid handling with features that address issues like cross-contamination and dispenser clogging. PolyPico's versatile solutions include both standard and customized services, utilizing simple disposable dispensing cartridges to enhance usability and reduce waste. The company's multidisciplinary team possesses expertise in micro-fluidics, electronics, software development, mechanical engineering, and biotechnology, driving ongoing research and development to revolutionize the dispensing of bio-materials and other liquids.

Nanografi, established in 2011 at METU Technopolis, has been at the forefront of graphene production, advanced materials and nanotechnology. In 2020, Nanografi launched the most efficient and largest graphene mass production facility, making it one of the pioneering companies in the world. For over a decade, Nanografi has remained a powerful solution partner in advanced material technologies. Operating under Ahlatcı Holding, Nanografi is committed to innovation and anticipates the future's technological advancements and needs. Since 2011, leveraging its experience in high-tech solutions across more than 100 countries, Nanografi takes pride in contributing to thousands of valuable research studies and technologies, guided by its developed technologies and scientific investigations. Nanografi, a leading player in present and upcoming sectors like advanced material technologies, high-security authentication, biotechnology, and smart packaging technologies, remains committed to creating value with its international quality standards.

Mimetis Biomaterials SL is a Spanish company founded in 2013, specializing in the design and manufacture of biomimetic bone graft substitutes for medical applications in dental, craniomaxillofacial, and orthopedic sectors. The company focuses on creating synthetic bone grafting solutions that mimic the properties of natural bone, thereby facilitating the colonization of grafts by bone cells and improving outcomes in complex cases. Mimetis offers a range of products, including biomaterial granules and patient-specific 3D-printed grafts, to address various bone defect filling needs. In addition to its product offerings, the company provides consulting, original equipment manufacturing, and co-development services to clinicians. Mimetis Biomaterials was previously known as Subtilis Biomaterials S.L. until its name change in January 2016 and is headquartered in Barcelona, Spain.

High Efficiency Water Condensing Biomembranes.ThinAir is tackling one of the three biggest problems on the planet, water scarcity. ThinAir has developed a bio-membrane that condenses water from air efficiently and energy-free. Inspired by the potential of biomimicry,they've harnessed the way beetles capture water even in the driest habitats in the world. The technology will facilitate agriculture and provide clean water for human consumption in areas where clean water is scarce.

BIA doo has consulting sales and technical support in the fields of biotechnology, chromatography, organic synthesis, sample preparation, laboratory equipment, and software for laboratories. It is a supplier of laboratory and process equipment.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

Founded in Sweden in 2011, Brain Stimulation specializes in innovative neurological rehabilitation. They leverage brain plasticity research to develop effective, individualized care for stroke, dementia, traumatic brain injuries, and other degenerative brain diseases.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

FreezeM is a company focused on advancing the use of insects as a sustainable protein source for the animal feed industry. Recognizing the potential of insects to address the growing demand for alternative protein, FreezeM develops innovative preservation technologies that facilitate large-scale freezing of insect species. This process aims to create a reliable supply of ready-to-use suspended neonates and frozen eggs, akin to agricultural seed production, which can overcome challenges related to availability, cost, and regulatory constraints. By establishing global stocks of beneficial insects, FreezeM supports various applications, including protein for animal feed, biological pest control, and species preservation, ultimately contributing to a more sustainable food system.

Better Juice Ltd., established in 2017 and headquartered in Rehovot, Israel, specializes in developing biotechnology systems that reduce sugar content in fruit juices using non-GMO methods. The company, founded by a team of experienced food industry professionals including a biochemist and microbiology academician, aims to provide consumers with healthier beverage options while maintaining natural flavors. Better Juice's technology converts monosaccharides and disaccharides into prebiotic fibers and sugars, enabling industrial juice producers to lower or eliminate sugar content in their products through a single-step process. The company is supported by The Kitchen FoodTech Hub – Strauss Group’s incubator, which fosters innovative food-tech ventures aiming to disrupt the global food system positively.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.

Ecohelix harnesses underutilized lignocellulosic side streams from the pulp industry into valuable, sustainable products. Utilizing a patented enzymatic process, Ecohelix converts residual lignin and hemicellulose into WOODMER®, a biodegradable polymer used in packaging, adhesives, and paper chemicals.

TargImmune Therapeutics is a Swiss biotech company specializing in targeted onco-immunotherapy drug development. Its core technology, CTPIC, employs a non-viral vector to target and destroy cancer cells expressing specific receptors while stimulating an immune response.

Pre Diagnostics is a Norwegian biomarker diagnostics company focused on the early detection of neurodegenerative diseases, especially Alzheimer’s disease. It develops blood-based in vitro diagnostic tests that capture disease-specific systemic responses, including intracellular analysis of monocytes to assess beta-amyloid clearance, with the aim of identifying disease onset before symptoms, improving patient stratification, and supporting precision medicine through laboratory services that back the diagnostic workflow.

Espansione Group is a medical technology company specializing in the development and distribution of innovative, non-invasive devices for ophthalmology. Their product portfolio includes proprietary photobiomodulation devices, light therapy systems using red, blue, and ultraviolet light, and diagnostic tools for eye screening. These solutions are designed to enhance patient outcomes by leveraging advanced, science-driven therapies, primarily serving the ophthalmology field.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

MycoSolutions AG is a pioneering company based in St. Gallen, Switzerland, specializing in the development of customized soil additives aimed at protecting and preserving trees, particularly veteran specimens. As a spin-off from the Emma division "Applied Wood Materials," the company leverages the expertise of its founders and employees to become a technology leader in the use of mushrooms for environmental applications. MycoSolutions offers a range of services including the diagnosis of fungal pathogens, tree assessments, and the development of custom plant growth promoters. Additionally, the company conducts visual inspections, hazard assessments, and provides technical support through workshops and consultancy. With a commitment to sustainability, MycoSolutions aims to replace conventional wood preservatives and pesticides with eco-friendly mushroom-based products, addressing the significant environmental impact of traditional chemicals used in agriculture and forestry.

Inflection Biosciences Ltd. is a drug development company based in Dublin, Ireland, specializing in the discovery and development of small molecule therapeutics aimed at treating cancer. Founded in 2012, the company focuses on identifying promising early-stage cancer research from academic institutions and other organizations worldwide. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors, which are currently in preclinical development. Inflection Biosciences is committed to advancing these programs through preclinical and early clinical stages, with the intention of partnering with larger pharmaceutical companies for subsequent development and commercialization. The leadership team, comprising individuals with over 60 years of industry experience, leverages a global network of potential partners and service providers to enhance its research and development efforts.

Surflay Nanotec focuses on functional surfaces, nanoscale coatings, polymers and microsensors. Their aim at Surflay is to rapidly deliver product-oriented scientific solutions to their customers and partners. They offer four inter-connected services: Contract research and surface solutions: surface modification and functionalization, Layer-by-Layer (LbL) coatings Fluorescent labeled polymers Nanostructures / Microstructures / Beads Microsensors: bioanalysis, pH, temperature & more

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Vetherapy Corp., established in 2015 and headquartered in San Francisco, specializes in veterinary regenerative medicine and tissue engineering. The company produces stem cell therapy products for cats, dogs, and horses, focusing on accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy's offerings include stem cell and platelet-rich plasma (PRP) banking services, ensuring veterinarians have access to safe and efficient products for various animal health conditions.

Clover Bioanalytical is a bioinformatics company focused on developing software solutions for bioanalytical chemistry and clinical diagnostics, particularly utilizing mass spectrometry. Established by a team of Ph.D. graduates with extensive experience in both research and business, the company excels in providing advanced data processing capabilities and statistical analysis in the biomedical field. Clover's expertise encompasses mass spectrometry applications, medical image processing, and both univariate and multivariate statistical analyses, making it adaptable to a variety of needs within the healthcare sector. The company emphasizes a customer-oriented approach, tailoring its systems to meet client goals and ensuring scalability. Furthermore, Clover aims to address significant scientific challenges in collaboration with hospitals, research centers, and biotechnology firms, employing artificial intelligence to aid in the rapid identification of microorganisms and enhance diagnostic processes.

Mecwins develops nanotechnological platforms for sensitive immunoassays, focusing on applications in oncology, cardiovascular disease, and infectious diseases. Their technology improves healthcare outcomes for at-risk populations.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Immunitrack is a company that specializes in the development of an AI-based prediction and assessment platform aimed at supporting the pharmaceutical and biotechnology sectors. It provides contracted research services that focus on predicting immune system responses to various pharmaceuticals. Additionally, Immunitrack produces reagents that facilitate the examination of immune reactions, thereby aiding biotech and pharmaceutical companies in the development of biologics and vaccines. Through its innovative approach, the company enables clients to enhance their research and development processes, ultimately contributing to advancements in medical therapies.

FGen GmbH is a Swiss company founded in 2011 as a spin-off from ETH Zurich, based in Basel. It specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries, facilitating the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in biotech, life sciences, and pharmaceuticals to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on optimizing microbial strains for biotechnological applications by integrating proprietary screening technology with biological engineering tools. This enables clients to achieve efficient and cost-competitive bioproduction of chemicals and proteins.

Polymer Factory, established in 2006 at the Royal Institute of Technology in Stockholm, Sweden, is a prominent supplier of advanced dendritic and polymeric materials, also offering contract research services. Its product range includes monodisperse dendritic polymers derived from 2,2-bis(methylol)propionic acid, such as biocompatible bis-MPA dendrimers and dendrons. The company specializes in the synthesis of high-quality macromolecules, custom materials, and calibrants for MALDI-ToF. Polymer Factory holds exclusive rights to several advanced materials and provides global access to polyester (Boltorn™) and polyester amide (Hybrane®) hyperbranched polymers for research purposes.

Scandinavian ChemoTech AB is a clinical development company headquartered in Lund, Sweden. It specializes in cancer care and pain management solutions, primarily through its innovative product, IQWave. This electroporation device uses short electric pulses in conjunction with localized or intravenous chemotherapy to treat various cancers, including head and neck squamous cell carcinoma, malignant melanoma, and breast adenocarcinoma, among others. The company's founders bring extensive experience in surgical oncology and clinical research, driving its commitment to advancing cancer treatment through genuine research and clinical trials. ChemoTech markets its products via distribution channels and a network of opinion leaders across regions such as South East Asia, India, and the Philippines. Established in 2013, the company continues to focus on developing effective therapies for cancer patients.

Nanovex Biotechnologies SL is an innovative technology-based spin-off from the University of Oviedo founded in 2014 that provides a wide range of services and products in the nanobiotechnology field.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

300K Solutions is a biotechnology company specializing in the development of innovative products for the storage and shipment of biological samples at room temperature. Its stabilization technology ensures secure preservation, optimizes storage space, and minimizes sample loss.

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art mass spectrometry based methodologies.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

AdFerTech is a company focused on developing innovative solutions for anaerobic digestion (AD) digestate. Its primary product is a cost-effective, bolt-on device designed for AD plants, which processes liquid digestate to concentrate nutrients and convert them into organic granular fertilizer. This value-added fertilizer is significantly easier to store and transport compared to traditional liquid fertilizers, providing a more efficient alternative that reduces the need for costly wastewater treatment. By enabling farmers to enhance their production through the use of this granular fertilizer, AdFerTech addresses the challenges associated with waste management in agricultural practices.

7scientists current academic research findings into practical solutions.

ImmuneBiotech AB, established in Lund, Sweden in 2013, specializes in the research and development of novel microbiome therapeutics. The company focuses on probiotic lactic acid bacteria and synbiotic formulations that target the gut microbiota and the immune system, aiming to prevent and treat autoimmune and chronic inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

Enzymlogic is a specialized company focused on enzymology and protein science, delivering innovative analytical solutions to the pharmaceutical and biotech sectors. They aim to enhance the drug discovery and development process, ultimately improving patient quality of life through safer and more effective therapeutics. By offering services that help determine kinetic profiles in drug interactions, Enzymlogic provides critical insights into the efficacy and safety of potential medications. Their mission is to support clients in maximizing their return on investment while fostering the development of groundbreaking therapies. Enzymlogic aspires to be a leading reference for organizations engaged in drug discovery through rational analysis approaches.

MaxWell Biosystems is a neuroscience-focused electronics and biotechnology company that develops instrumentation and solutions to advance neuroscience research and accelerate preclinical drug discovery. It provides functional cell imaging and electrophysiology platforms to study cellular function and network activity. The flagship MaxOne platform is a CMOS-based high-density microelectrode array that records and stimulates electrogenic cells in vitro, featuring thousands of electrodes, low-noise readout channels and multiple stimulation channels to enable single-cell and network parameter extraction for phenotypic screening and drug toxicity and efficacy testing. The integrated platform combines a sensor chip, acquisition hardware and software to deliver accurate results and speed up the characterization of cell function from months to weeks. The company, founded in 2016, is based in Zurich, Switzerland.

Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

Seaweed Solutions AS is a prominent seaweed cultivation and business development company established in 2009, focusing on large-scale ocean farming for diverse applications including food, feed, pharmaceuticals, and biomaterials. With a comprehensive control over the entire value chain, the company operates proprietary seed hatcheries, employs innovative deployment methods, and maintains processing plants. Seaweed Solutions is at the forefront of modern seaweed farming, utilizing its patented cultivation technology, the Seaweed Carrier, which is based on decades of accumulated expertise. The company operates the largest seaweed farms in Europe, primarily dedicated to brown macroalgae, and is staffed by a specialized international team versed in biology, marine engineering, biotechnology, and business. Seaweed Solutions aims to become the leading European supplier of cultivated biological seaweed and seaweed seeds while developing partnerships and providing turnkey solutions within cultivation technology, raw material sourcing, market development, and environmental services.

TransCure BioServices SAS is a biotechnology company based in Archamps, France, founded in 2012. The company specializes in vivo pharmacology preclinical services and offers unique research and development platforms, including its Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These innovative models are designed to enhance the drug profiling and development process for pharmaceutical companies, biotech firms, and academic researchers focusing on immuno-related diseases and anti-HIV/AIDS therapies. By providing access to its specialized platforms as fee-for-service offerings, TransCure BioServices enables clients to efficiently generate and characterize humanized mouse models that deliver predictive insights into human drug responses. This capability helps accelerate the development and commercialization of new therapies, ultimately allowing clients to bring effective treatments to market more quickly and cost-effectively.

Metys Pharmaceuticals is focused on developing MP-101, a small molecule drug aimed at preventing and treating chemotherapy-induced peripheral neuropathy, a common and distressing side effect of cancer treatments. MP-101 functions as an orally-active modulator of glutamate signaling in the spine and brain, a pathway that has been targeted for new central nervous system therapies. The drug is derived from a patent-pending non-racemic mixture of the enantiomers of dimiracetam, which has demonstrated enhanced pharmacological potency compared to traditional racemic mixtures. Metys Pharmaceuticals has secured exclusive global rights to racemic dimiracetam from Neurotune AG, along with comprehensive regulatory study data to support future clinical trials for MP-101. The company aims to leverage this data to advance its innovative approach in addressing neuropathic pain and other central nervous system disorders.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

ProtectPipe is a Finnish microbiotechnology company producing an innovative microbe solution that removes organic waste from drainpipes. The microbe solution moves to the areas with build-up in the pipes and devours the waste. That is an ecological way to stop the erosion in pipes and prevent any harmful waste from entering the fragile environment.

Vulcur Medtech is a medical device development company based in Vanløse, Denmark, established in 2018. The company specializes in wound healing through its innovative VulCur MedTech laser technology. This device is designed to target and eliminate biofilm-producing bacteria in chronic wounds by using laser pulses that penetrate tissue, effectively ablating bacteria while preserving human cells. By facilitating the healing of otherwise untreatable wounds, Vulcur Medtech's approach not only accelerates the healing process but also enhances patients' quality of life.

Algalif supplies astaxanthin products from microalgae, including ingredients and finished formulations. They help solve the nutritional needs of current and future generations through the development and delivery of sustainable microalgae ingredients. They also commercialize a range of immune-health ingredients, for use in food, beverages, nutraceuticals, sports nutrition, and personal care products.

Martin and Co Ltd was funded, for providing different R&D services in the field of chemistry method development, biotechnological process development and analytical chemistry method developments. Their company is located at Berlini Park (http://www.berlinipark.hu/), which is an incubation space for chemistry related start-ups in Budapest (formal buildings of Medicinal Chemistry research Center, which was shut down 10 years ago). We have all necessary laboratory units, toolkits and devices to carry out their research. Regarding analytical chemistry, we have Shimadzu Mass Spectrometer-2020(CL) and excess to other analytical units at the campus of Berlini Park. In summer of 2017, after the completion of RAID SME Instrument Phase 1 project by Tonosoft Ltd, the RAID knowledge and rights were transferred to Martin and Co Ltd. The patent about RAID project was prepared and submitted by Martin and Co Kft in October 2017.

Vetbiobank is a biotechnology company specializing in veterinary regenerative medicine. It focuses on developing and providing clinical-grade cell and tissue products derived from neonatal stem cells to veterinarians, aiming to improve animal care by managing chronic inflammatory conditions affecting joints, skin, digestive system, and mucous membranes.

AmyPore is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, specifically Alzheimer's and Parkinson's. Its lead product, AmyP53, is a chimeric peptide created using artificial intelligence applied to molecular neuroscience. This groundbreaking drug targets a common mechanism underlying both diseases by blocking the formation of neurotoxic structures, specifically oligomers of amyloid proteins, which are responsible for their progression. AmyP53 represents a novel therapeutic class, being the first molecule capable of addressing the shared pathophysiological aspects of Alzheimer's and Parkinson's diseases, thus providing new hope for patients affected by these conditions.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

Biowatch SA, founded in 2015 and headquartered in Martigny, Switzerland, has developed a biometric identification system that integrates into the buckle of a watchband, allowing for secure authentication through the unique patterns of veins on a user's wrist. The Biowatch functions as a user-friendly biometric reader, providing a security solution for mobile payments and smart device interactions. Users can enroll their vein patterns via an application, which enables them to connect their Biowatch to various devices and applications. Once enrolled, users can authenticate themselves by matching their vein patterns, allowing them to access services and premises without the need for traditional keys, passwords, or PIN codes. The technology aims to simplify and enhance security measures in everyday transactions and interactions.

Pila Pharma AB is a clinical stage biotech company based in Malmö, Sweden, focused on developing XEN-D0501, a potent and selective TRPV1 antagonist. This innovative compound is being investigated as a treatment for type 2 diabetes, obesity, and the rare painful condition known as erythromelalgia. XEN-D0501 has undergone testing in over 300 subjects during phase 1 and phase 2 trials, demonstrating a favorable safety profile in healthy volunteers and patients with various conditions, including overactive bladder disease and chronic cough. The compound has shown efficacy in improving glucose-stimulated insulin secretion in type 2 diabetics. Recent preclinical studies have completed successfully without any registered side effects, allowing XEN-D0501 to advance to longer clinical trials. In July 2022, Pila Pharma received US Orphan Drug Designation for this compound in the context of erythromelalgia.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

PreOmics GmbH is a biotechnology company based in Planegg, Germany, specializing in mass spectrometry (MS)-based proteomics. Founded in 2016 as a spin-off from the Max-Planck Institute of Biochemistry, PreOmics develops innovative tools and technologies aimed at enhancing protein analysis for researchers worldwide. The company's flagship product, the iST Kit, facilitates rapid and reproducible preparation of peptide mixtures from various starting materials, streamlining the sample preparation process within just one hour. PreOmics also offers high-throughput processing accessories and a robust platform that leverages liquid chromatography coupled with mass spectrometry to enable comprehensive protein identification, quantification, and analysis of post-translational modifications. Through its advanced solutions, PreOmics supports the scientific community in accelerating discovery and understanding of protein interactions and functions.

Biom'Up designs, develops and manufactures absorbable medical devices based on collagen technology for biosurgery. The company offers Hemoblast products for hemostasis and related laparoscopic applicators, and Hemosnow solutions for guided tissue regeneration, serving orthopedics, spine, cardiac, general, maxillofacial, dental and other surgical specialties. It markets its products in Europe and the United States. Biom'Up was founded in 2005 and is based in Saint-Priest, France.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

BIOsens Inc. specializes in developing biosensors for the rapid quantitative diagnostics of food toxins, particularly mycotoxins. The company offers a testing device that allows for easy sample preparation and delivers results within 15 minutes. These results are stored in the cloud, utilizing Internet of Things (IoT) technology. By providing efficient and reliable testing solutions, BIOsens aims to enhance food safety and help consumers trust the safety of their food products.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

ChemiCare is a biotech company founded in 2016 that focuses on discovering and developing therapies for calcium-related rare genetic diseases. It aims to restore normal intracellular calcium levels by modulating store-operated calcium entry with drug-like modulators, crafted through click chemistry to enable exploration of chemical space and rapid refinement of candidate compounds, thereby accelerating drug discovery and development.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

Microbium is an innovative research and development company specializing in microbiological detection protocols tailored for specific industrial applications. Founded to address the pressing challenges posed by microbial contamination, Microbium collaborates closely with national laboratories and analytical organizations in Russia, Denmark, and Slovenia. The company develops advanced electronic devices that automate the detection and counting of harmful microorganisms, such as E. coli and coliforms, in drinking water and various industrial products. Additionally, Microbium employs a bioremediation process to effectively eliminate these microorganisms from water supply systems and production lines, thereby helping clients reduce contamination hotspots, lower production costs, and minimize their environmental impact.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

Eden Microfluidics is a young innovative company founded in 2017. The company aims to provide advanced and certified materials, microfabrication and microfluidics solutions to both researchers and industrial partners. Eden Microfluidics is driven by a team of talented and passionate scientists, innovators and entrepreneurs, thriving to develop radical microfluidic solutions, for biomedical to environmental challenges. All together, they assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems. Eden Microfluidics is here to offer you access to the latest, up-to-date microfluidic science and technology.

NapiFeryn BioTech specializes in the extraction of protein from waste streams generated during rapeseed oil production. The company employs advanced biorefinery technology to convert these side streams into functional and nutritional protein isolates and concentrates. This innovative process is more sustainable and efficient compared to traditional methods, enabling the production of high-quality, plant-based proteins. NapiFeryn's products serve as a cost-effective and sustainable alternative to animal-derived proteins, making them suitable for a variety of applications in both food and feed industries. Through its focus on sustainability, NapiFeryn BioTech supports oil mills and food producers in the development of natural bio proteins, addressing the growing demand for environmentally friendly protein sources.

InSCREENeX GmbH is a biotechnology company located in Braunschweig, Germany, and operates as a spin-off of the Helmholtz Centre for Infection Research, founded by Dr. Roland Schucht. The company specializes in developing cellular screening technologies that aim to expedite the drug discovery process for pharmaceutical and drug development firms. By utilizing advanced genetic manipulation techniques, InSCREENeX creates innovative and user-friendly mammalian cell systems that serve as effective decision-making tools in drug development. These systems are designed to enhance biological relevance and convenience, addressing the time and cost challenges associated with biopharmaceutical drug discovery. Additionally, InSCREENeX is developing complementary technology platforms that facilitate the generation of cell lines for primary screening and the design of physiologically relevant cell types for secondary screening and profiling.

EmeraMed Limited is a privately held biotechnology company based in the Republic of Ireland, with operations in Ireland, Sweden, and the United States. The company's ownership group consists mainly of physicians, dentists, and patients who have previously used its products as dietary supplements. EmeraMed is focused on developing a lipophilic antioxidant capable of penetrating the blood-brain barrier. The company's primary goal is to chelate free iron and various heavy metals, including mercury and lead, which can generate harmful free radicals. By addressing these issues, EmeraMed aims to help healthcare providers restore normal mitochondrial function and enhance overall health.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

Calyxia designs and produces microcapsules ranging from one to fifty microns. These microcapsules protect active ingredients from damage during industrial processes, releasing them at optimal times and locations for enhanced performance. This results in cleaner formulations with improved efficiency.

SagaNatura is an Icelandic biotech company that specializes in the development, production, and export of health products derived from premium Icelandic ingredients. The company focuses on the organic herb Archangelica Angelica and high-quality Astaxanthin, offering a range of consumer products that are safe, vegan-friendly, and of Icelandic origin. SagaNatura operates under two primary brands, SagaMedica, established in 2000, and KeyNatura, launched in 2014. The company aims to promote healthier lifestyles through its clean-label nutrition products, which address various health issues, including vision, skin health, energy, and concentration. By leveraging Iceland's pristine environment, SagaNatura is committed to providing high-quality health solutions that contribute to the well-being of consumers.

WeedOUT is a biotechnology company dedicated to developing innovative weed control solutions that minimize reliance on toxic herbicides. The company specializes in creating novel bio-herbicides designed to combat resistant weeds through a unique approach that leverages sterility. By utilizing weed pollen applied during the flowering period, WeedOUT's products effectively prevent the generation of viable seeds from resistant weeds, offering a natural method for their eradication. This approach not only addresses the challenge of chemical-resistant weeds but also promotes environmentally friendly practices within the agricultural sector.

Toleranzia is a Swedish biotechnology company developing drugs that harness the immune system's power to treat rare autoimmune diseases. Its pipeline includes TOL2 for myasthenia gravis and TOL3 for ANCA vasculitis, both targeting disease-specific proteins.

Bioithas is a medical research company focused on developing natural treatments aimed at improving health and quality of life. The company dedicates its efforts to conducting rigorous clinical trials to create personalized therapies that address the root causes of health issues rather than merely alleviating symptoms. By directing research toward unique biotechnological advancements, Bioithas seeks to generate valuable projects that contribute to meaningful scientific outcomes, ultimately enhancing the well-being of individuals.